---
categories:
- medicine
- 検査
- 血液
date: 1999-01-01 00:00:00 +0900
tags:
- medicine
- 検査
- 血液
- private-memo
- AYOR
title: 凝固
type: page
---

### 凝固因子

|CLOTTING FACTOR|SYNONYM|DISORDER|
|:----|:----|:----|
|I|Fibrinogen|Congenital deficiency (afibrinogenemia) or dysfunction (dysfibrinogenemia)|
|II|Prothrombin|Congenital deficiency or dysfunction|
|V|Labile factor, proaccelerin|Congenital deficiency (parahemophilia)|
|VII|Stable factor or proconvertin|Congenital deficiency|
|VIII|Antihemophilic factor|Congenital deficiency is hemophilia A (classic hemophilia)|
|IX|Christmas factor|Congenital deficiency is hemophilia B|
|X|Stuart-Prower factor|Congenital deficiency|
|XI|Plasma thromboplastin antecedent|Congenital deficiency, sometimes referred to as hemophilia C|
|XII|Hageman factor|Congenital deficiency is not associated with clinical symptoms|
|XIII|Fibrin-stabilizing factor|Congenital deficiency|

### 凝固基準値 (Nelson 8th ed.)

|TEST|28-31 WK GESTATION|30-36 WK GESTATION|FULL TERM|1-5 YR|6-10 YR|11-18 YR|ADULT|
|:----|:----|:----|:----|:----|:----|:----|:----|
|SCREENING TESTS|
|Prothrombin time (PT) (sec)|15.4 (14.6-16.9)|13.0 (10.6-16.2)|13.0 (10.1-15.9)|11 (10.6-11.4)|11.1 (10.1-12.0)|11.2 (10.2-12.0)|12 (11.0-14.0)|
|Activated partial thromboplastin time (APTT) (sec)|108 (80-168)|53.6 [27.5-79.4][‡](§)|42.9 [31.3-54.3](‡)|30 (24-36)|31 (26-36)|32 (26-37)|33 (27-40)|
|Bleeding time (BT) (min)| | | |6 [2.5-10](‡)|7 [2.5-13](‡)|5 [3-8](‡)|4 (1-7)|
|PROCOAGULANTS|
|Fibrinogen|256 (160-550)|243 [150-373][‡](§)|283 (167-399)|276 (170-405)|279 (157-400)|300 (154-448)|278 (156-40)|
|Factor II|31 (19-54)|45 [20-77](‡)|48 [26-70](‡)|94 [71-116](‡)|88 [67-107](‡)|83 [61-104](‡)|108 (70-146)|
|Factor V|65 (43-80)|88 [41-144](§)|72 [34-108](‡)|103 (79-127)|90 [63-116](‡)|77 [55-99](‡)|106 (62-150)|
|Factor VII|37 (24-76)|67 [21-113](‡)|66 [28-104](‡)|82 [55-116](‡)|86 [52-120](‡)|83 [58-115](‡)|105 (67-143)|
|Factor VIII procoagulant|79 (37-126)|111 (5-213)|100 (50-178)|90 (59-142)|95 (58-132)|92 (53-131)|99 (50-149)|
|von Willebrand factor (VWF)|141 (83-223)|136 (78-210)|153 (50-287)|82 (60-120)|95 (44-144)|100 (46-153)|92 (50-158)|
|Factor IX|18 (17-20)|35 [19-65][‡](§)|53 [15-91][†](‡)|73 [47-104](‡)|75 [63-89](‡)|82 [59-122](‡)|109 (55-163)|
|Factor X|36 (25-64)|41 [11-71](‡)|40 [12-68](‡)|88 [58-116](‡)|75 [55-101](‡)|79 (50-117)|106 (70-152)|
|Factor XI|23 (11-33)|30 [8-52][‡](§)|38 [40-66](‡)|30 [8-52](‡)|38 (10-66)|74 [50-97](‡)|97 (56-150)|
|Factor XII|25 (5-35)|38 [10-66][‡](§)|53 [13-93](‡)|93 (64-129)|92 (60-140)|81 [34-137](‡)|108 (52-164)|
|Prekallikrein (PK)|26 (15-32)|33 [9-89](‡)|37 [18-69](‡)|95 (65-130)|99 (66-131)|99 (53-145)|112 (62-162)|
|High molecular weight kininogen (HMWK)|32 (19-52)|49 [9-89](‡)|54 [6-102](‡)|98 (64-132)|93 (60-130)|91 (63-119)|92 (50-136)|
|Factor XIIIa[¶]| |70 [32-108](‡)|79 [27-131](‡)|108 (72-143)|109 (65-151)|99 (57-140)|105 (55-155)|
|Factor XIIIb[¶]| |81 [35-127](‡)|76 [30-122](‡)|113 [69-156](‡)|116 [77-154](‡)|102 (60-143)|98 (57-137)|
|ANTICOAGULANTS|
|Antithrombin-III (AT-III)|28 (20-38)|38 [14-62][‡](§)|63 [39-87](‡)|111 (82-139)|111 (90-131)|106 (77-132)|100 (74-126)|
|Protein C|28 [12-44][‡](§)|35 [17-53](‡)|66 [40-92](‡)|69 [45-93](‡)|83 [55-111](‡)|96 (64-128)|
|Protein S:|
|Total (U/mL)| |26 [14-38][‡](§)|36 [12-60](‡)|86 (54-118)|78 (41-114)|72 (52-92)|81 (61-113)|
|Free (U/mL)| | | |45 (21-69)|42 (22-62)|38 (26-55)|45 (27-61)|
|Plasminogen (U/mL)| |170 [112-248](¶)|195 [125-265](¶)|98 (78-118)|92 (75-108)|86 (68-103)|99 (77-122)|
|Tissue type plasminogen activator (TPA) (ng/mL)| |8.48 (3.00-16.70)|9.6 (5.0-18.9)|2.15 [1.0-4.5](‡)|2.42 [1.0-5.0](‡)|2.16 [1.0-4.0](‡)|1.02 (0.68-1.36)|
|Antiplasmin (α2AP) (U/mL)| |78 (40-116)|85 (55-115)|105 (93-117)|99 (89-110)|98 (78-118)|102 (68-136)|
|Plasminogen activator inhibitor-I (PAI-1)| |5.4 [0.0-12.2](‡)|6.4 (2.0-15.1)|5.42 (1.0-10.0)|6.79 [2.0-12.0](‡)|6.07 [2.0-10.0](‡)|3.60 (0.0-11.0)|

* All factors except fibrinogen are expressed as units/mL (fibrinogen
in mg/mL), in which pooled normal plasma contains 1 U/mL. All data are
expressed as the mean, followed by the upper and lower boundaries
encompassing 95% of the normal population (shown in parentheses). †
Levels for 19-27 wk and 28-31 wk gestation are from multiple sources and
cannot be analyzed statistically. ‡ Values are significantly different
from those of adults. § Values are significantly different from those of
full-term infants. ¶ Value given as CTA (Committee on Thrombolytic
Agents) units/mL.

[^1]: 小児臨床検査ガイド
